Antitumor effect of blister beetles: An ethno-medicinal practice in Karbi community and its experimental evaluation against a murine malignant tumor model

Excretory/Secretory Products (ESPs) of the nematode Trichinella spiralis contain antitumor-active substances that inhibit tumor growth. Mature dendritic cells (DCs) play a critical role in the antitumor immunity of the organism. As pathogen-derived products, it ought to be discussed whether T. spiralis ESPs will reduce the antitumor effect of mature DCs from the host before it is applied to patients’ tumors. Therefore, the aim of this work was to evaluate the immunological effect of DCs stimulated by T. spiralis ESPs in H22 tumor-bearing mice. H22 tumor model mice in this study were randomly divided into four groups according to the treatment: PBS control group, ESP group, DCs group, and DCs stimulated with T. spiralis ESP (ESP+DCs group). The antitumor effect was evaluated by tumor inhibition rate and cytokine detection using ELISA. The results showed significant inhibition in tumor growth in the ESP+DCs, DCs and ESP groups when compared with the PBS control group (p < 0.01, p < 0.01, and p < 0.05, respectively). However, no significant difference was observed on tumor inhibition rates between the ESP+DCs and DCs groups. The decrease in IL-4, IL-6, and IL-10, and the increase in IFN-γ between the DCs and ESP+DCs groups were also not significant. Therefore, DCs stimulated by ESP did not reduce the antitumor effect of mature DCs, which demonstrated that the T. spiralis ESP would not affect the antitumor effect of mature DCs by modulating the immune response of the host, and that ESPs are safe in antitumor immunology when applied in a tumor model mice.

Download Full-text

Transarterial Chemoembolization Using Sorafenib in a Rabbit VX2 Liver Tumor Model: Pharmacokinetics and Antitumor Effect

Journal of Vascular and Interventional Radiology ◽

10.1016/j.jvir.2016.02.032 ◽

2016 ◽

Vol 27 (7) ◽

pp. 1086-1092 ◽

Cited By ~ 3

Author(s):

Gyoung Min Kim ◽

Man Deuk Kim ◽

Do Young Kim ◽

Se Hoon Kim ◽

Jong Yun Won ◽

...

Keyword(s):

Liver Tumor ◽

Transarterial Chemoembolization ◽

Antitumor Effect ◽

Tumor Model

Download Full-text

Antitumor effect of palmitic acid‐conjugated Dsi RNA for colon cancer in a mouse subcutaneous tumor model

Chemical Biology & Drug Design ◽

10.1111/cbdd.13454 ◽

2019 ◽

Vol 93 (4) ◽

pp. 570-581 ◽

Cited By ~ 1

Author(s):

Takanori Kubo ◽

Yoshio Nishimura ◽

Yuta Hatori ◽

Reiko Akagi ◽

Keichiro Mihara ◽

...

Keyword(s):

Colon Cancer ◽

Palmitic Acid ◽

Antitumor Effect ◽

Tumor Model ◽

Subcutaneous Tumor

Download Full-text

Efficacy of Gemcitabine on Intracranial Erlich Tumor and its Determinants

Drug Research ◽

10.1055/a-0824-6325 ◽

2019 ◽

Vol 70 (02/03) ◽

pp. 86-90

Author(s):

Alexander N. Stukov ◽

Vladimir G. Bespalov ◽

Valerij A. Alexandrov ◽

Alexander L. Semenov ◽

Galina S. Kireeva ◽

...

Keyword(s):

Brain Tumors ◽

Antitumor Effect ◽

Tumor Model ◽

Intracranial Tumor ◽

Therapeutic Activity ◽

Ehrlich Tumor ◽

Limited Ability ◽

Wide Range ◽

Therapeutic Doses ◽

Sufficient Concentration

AbstractGemcitabine is quite effective in the treatment of brain tumors, although this drug has a limited ability to overcome the blood-brain barrier (BBB). Aim of study is to assess the therapeutic efficacy of gemcitabine and other drugs with different permeability of BBB in the model of intracranial tumor. The therapeutic activity of gemcitabine, carmustine, cyclophosphamide and cisplatin was studied in mice with intracranially implanted Ehrlich tumor, and also gemcitabine in various doses - with intramuscularly implanted tumor. On intracranial tumor model gemcitabine (25 mg/kg) increased the life span (ILS) by 60−89% (p<0.001), despite the fact that its permeability of the BBB is about 10%. Therapeutic activity of carmustine, cyclophosphamide and cisplatin (ILS were 44, 22 and 11%, respectively) corresponds with the BBB permeability for these drugs (90, 20 and 8%, respectively). On intramuscular tumor model, gemcitabine showed significant antitumor effect at both 25 and 2.5 mg/kg, indicating a wide range of therapeutic doses of this drug. Pronounced therapeutic effect of gemcitabine on intracranial tumor most likely is due to the small but sufficient concentration of the drug that overcomes the BBB.

Download Full-text